1. Introduction {#s0005}
===============

Senescent cells accumulate with age in a wide range of tissues. Frequencies in excess of 5%, and sometimes as much as 20% and more, have been reported in tissues from old animals both with high (white blood cells ([@bb0015]); crypt enterocytes ([@bb0145], [@bb0315])) and low (dermal fibroblasts ([@bb0100]), hepatocytes ([@bb0145], [@bb0315]), fat progenitors ([@bb0280]), osteocytes ([@bb0110])) proliferation rates as well as in postmitotic tissues (neurons ([@bb0140])). The rate of accumulation of senescent cells in liver and intestinal crypts predicts median and maximum lifespan of mice in cohorts with widely different aging rates (e.g. late generation *TERC −/−* vs wt and dietary restricted C57Bl/6) ([@bb0145]). More importantly, interventions that selectively ablate senescent cells by genetic and/or pharmacologic means may improve healthspan and lifespan in mice ([@bb0025], [@bb0090], [@bb0340]).

Mechanistically, the age-promoting effects of senescence are associated with the restriction of regenerative capacity of stem and progenitor cells ([@bb0060], [@bb0145]) as well as the secretion of bioactive molecules (the so-called SASP ([@bb0070])), specifically pro-inflammatory and matrix-modifying peptides. Pro-aging effects of senescent cells are aggravated by SASP and, possibly, other paracrine mediators which can propagate senescence from cell to cell as a bystander effect ([@bb0230]). In recent years, evidence has been mounting that senescent cells impact on their environment via yet another principal pathway: mitochondrial dysfunction.

Along with cell senescence, mitochondrial dysfunction is another essential 'hallmark of aging' ([@bb0180]), and the two have been independently identified as important drivers of aging ([@bb0115]). Importantly, they are closely interlinked: mitochondrial dysfunction drives and maintains cell senescence ([@bb0075], [@bb0240], [@bb0335]), while at the same time cell senescence, specifically persistent DNA damage response signalling, directly contributes to Senescence-Associated Mitochondrial Dysfunction (SAMD) ([@bb0235]). Despite the close interdependent relationship between senescence and SAMD, the true complexity of these interactions and their role in aging remains to be elucidated. For example, it is currently unclear how much of the mitochondrial dysfunction that has been observed at tissue level during aging is actually associated with senescence at a cellular level. Furthermore, despite its central contribution to the senescent phenotype ([@bb0075]), it is not clear how mitochondria become dysfunctional in senescence. Importantly, an understanding of the potential consequences of SAMD in the context of tissue aging is only beginning to emerge. In this review, we will explore the following hypotheses:1.Senescence results in dysregulated mitophagy that drives SAMD; and2.SAMD is a significant cause of (accelerated) aging.

We conclude that mitophagy, SAMD and SASP are tightly interlinked in cell senescence by a network of inter-related feedback signalling pathways and that SAMD may be an essential cause of metabolic dysfunction in aging.

2. Dysfunctional mitochondria accumulate in senescent cells {#s0010}
===========================================================

It is well established that not only cell size but also mitochondrial mass increases significantly in senescent cells ([Table 1](#t0005){ref-type="table"}). Kinetic studies in stress-induced senescence showed that the increase in mitochondrial mass is a fast but not immediate process, occurring with a delay of 2--3 days after the peak in DNA damage but before a robust SASP is established ([@bb0235]). As with most other senescence phenotypes, mitochondrial accumulation has preferentially been studied in fibroblasts, but occurs also in senescent epithelial cells ([@bb0130]), hepatocytes ([@bb0075]), enterocytes ([@bb0145]) or neurons that develop a senescence-like phenotype in response to persistent DNA damage ([@bb0140]). In oncogene-induced senescence, the activity of the mitochondrial 'gatekeeper' protein pyruvate dehydrogenase is increased by simultaneous suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2). The resulting combined activation of PDH enhanced the use of pyruvate in the tricarboxylic acid cycle, causing increased respiration and redox stress ([@bb0160]). In senescent cells, the expression of fission mediators Drp1 and Fis1 ([@bb0185]) and frequencies of both fusion and fission events ([@bb0080]) are reduced, resulting in enhanced connectivity of the mitochondrial network.Table 1Metabolic changes in senescence and aging.Table 1Mitochondrial massMPP or respiratory couplingROS productionRSIncreased ([@bb0240])Decreased ([@bb0235], [@bb0240])Increased ([@bb0240])OISIncreased ([@bb0205])Decreased ([@bb0205])Increased ([@bb0205])SISIncreased ([@bb0235], [@bb0305])Decreased ([@bb0235], [@bb0240])Increased ([@bb0235], [@bb0305])Aging in vivoDifferent results depending on tissue and methodologyDecreased e.g. liver ([@bb0200]); brain ([@bb0065]); skeletal muscle ([@bb0250])Increased e.g. liver ([@bb0200]); heart ([@bb0245]); skeletal muscle ([@bb0195])[^1]

In functional mitochondria, oxygen uptake, ATP production, membrane potential and generation of ROS are tightly regulated to maintain the redox balance ([@bb0040]). While there is no simple correlation between membrane potential and superoxide production by the electron transport chain, mitochondria that accumulate in senescence often show a decreased membrane potential and at the same time produce increased levels of ROS (Table 1), suggesting dysfunctionality. In accordance with this notion, the capacity of senescent cells to regulate \[Ca^2 +^\]~i~ is decreased and a retrograde response is initiated ([@bb0240]). In mitochondria from senescent cells, the Respiratory Control Ratio (RCR, the ratio of oxygen uptake in state 3 (presence of ATP) to state 4 (presence of oligomycin)), is much lower than in young cells (Table 1), specifically if respiration is fuelled by complex I-linked substrates. Together, these data show that the mitochondria that accumulate during cell senescence are dysfunctional. We propose the notion of Senescence-Associated Mitochondrial Dysfunction (SAMD) for this phenotype.

It should be noted that decreased activity of complex I, decreased coupling and increased ROS production accompany the aging process in many tissues (Table 1), paralleling the increase in the frequency of senescent cells in the same tissues ([@bb0145], [@bb0315]). Mitochondrial dysfunction has a profound effect on cellular bioenergetics ([Fig. 1](#f0005){ref-type="fig"}): First, increased mitochondrial mass is reflected by a significantly higher absolute oxygen consumption rate per cell in senescence ([Fig. 1](#f0005){ref-type="fig"}A). Second, in senescent cells the fraction of ATP produced by mitochondrial oxidative phosphorylation decreases, while relatively more ATP is generated by glycolysis ([Fig. 1](#f0005){ref-type="fig"}B). Thus, both the increase in mitochondrial abundance and the shift towards a more glycolytic mode of ATP production appear as compensatory responses to mitochondrial dysfunction. Evidently, early occurrence of mitochondrial dysfunction during the induction of cell senescence could set off a number of different cellular responses and signalling pathways as well as reducing the capacity to respond to peak energy demands.Fig. 1Senescence drives changes in cell bioenergetics. Human MRC5 fibroblasts were either fully proliferation competent (young) or replicatively senescent (sen). Cellular oxygen consumption rates and extracellular acidification rates were assayed in medium containing 5 mM glucose, 2 mM [l]{.smallcaps}-glutamate and 3% FBS using a Seahorse XF24 analyzer. A) Oxygen consumption rates showing basal condition, and after sequential additions of the following drugs as indicated: oligomycin (to block ATP synthesis), the uncoupler FCCP (to stimulate respiration) and Antimycin A (to block the electron transport chain at complex III). B) Relative glycolytic and mitochondrial ATP production rates were calculated using the data generated in Fig. 1A as described ([@bb0215]). Data are mean ± SD from 20 samples from 2 independent experiments.Fig. 1

In ionizing radiation (IR)-induced senescence, activation of p53 causes induction of the master regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptor gamma, coactivator 1 beta (PGC-1β) driving an increase in mitochondrial mass. This is not due to a direct transactivation of PGC-1β, rather, p53 triggers murine double minute 2 (MDM2)-mediated hypoxia inducible factor 1 α (HIF-1α) degradation, leading to release of PGC-1β inhibition by HIF-1α ([@bb0035]). This is in accordance with data showing HIF-1a as inducer of mitophagy ([@bb0020]). In apparent contrast, Sahin et al. ([@bb0265]) described profound repression of both PGC-1α and PGC-1β, associated with impaired mitochondrial biogenesis, in mice null for either telomerase reverse transcriptase (*TERT*) or telomerase RNA component (*TERC*) genes. Telomerase knock-out mice show enhanced frequencies of senescent cells ([@bb0060], [@bb0140], [@bb0145], [@bb0235]) and mitochondrial dysfunction ([@bb0295]) in multiple tissues. A kinetic quantitative analysis of the induction of stress-dependent senescence resolved this contradiction ([@bb0080]): PGC-1α (and presumably PGC-1β) was upregulated only temporarily during the early DNA damage response phase, but became down-regulated in established senescence. This transient upregulation caused only a minor increase in mitochondrial mass, while the majority of mitochondrial accumulation occurred later, when PGC-1β was already downregulated below control values. With progression of senescence, mitochondria accumulated into a progressively more rigid network characterized by low fusion and fission rates. Together with functional deterioration of accumulating mitochondria this suggested that a delay in autophagic degradation of defective mitochondria via a process called mitophagy (see next chapter) is a major contributor to mitochondria accumulation in stress-induced senescence.

3. Autophagy is an essential mitochondrial quality control mechanism implicated in senescence {#s0015}
=============================================================================================

3.1. Autophagy and cell senescence {#s0020}
----------------------------------

Autophagy is a collective term for several cellular pathways facilitating degradation of intracellular components by lysosomal proteases. Amongst autophagy pathways macroautophagy (hereafter for simplicity called autophagy) is the best studied process ([Fig. 2](#f0010){ref-type="fig"}A). Autophagy begins with the engulfment of surplus or damaged proteins and entire organelles by double membraned vesicles called autophagosomes which eventually fuse with lysosomes. The resulting hybrid organelle is called autolysosome and allows degradation of autophagy substrates and subsequent release of basic components such amino acids, lipids and nucleotides back into the cytoplasm for biosynthetic processes and energy generation. Autophagy activity is increased in conditions of nutrient deprivation sensed via the mechanistic Target of Rapamycin Complex 1 (mTORC1) pathway and serves as a recycling process necessary for cell survival during starvation. Importantly, autophagy is also a quality control mechanism selectively scavenging potentially toxic cellular components. Selective autophagy is classified on the basis of specific substrates with mitophagy being the most relevant to the topic of this review. Autophagy has been implicated in the development of cellular senescence. However, this relationship appears to be complex and often contradictory ([Fig. 2](#f0010){ref-type="fig"}B). Thus, on one hand autophagy has been suggested to act as a pro-senescence mechanism. Indeed, studies have demonstrated that autophagy promotes the process of oncogene-induced senescence (OIS). Overexpression of the autophagy gene ULK3 was found to enhance autophagy and stimulate senescence induced by the RAS oncogene in human fibroblasts ([@bb0345]). This effect of autophagy was suggested to be mediated by a specialized intracellular structure called TOR-autophagy spatial coupling compartment (TASCC) ([@bb0225]). TASCC was shown to allow simultaneous and compartmentalised generation of amino acids and other metabolites by autophagy. Conversely, activation of the mTORC1 signalling pathway, a negative regulator of TASCC, promoted increased production of SASP factors thus facilitating acquisition of senescence phenotypes. Knockdown of the essential autophagy genes *Atg5* and *Atg7* was found to decrease SASP and bypass senescence ([@bb0225], [@bb0345]). Likewise, overexpression of the inhibitors of cyclin-dependent kinases p16(INK4A), p19(ARF) or p21(WAF1/CIP1) induced not only senescence as expected but also autophagy ([@bb0055]). Furthermore, autophagy induction by a proteolytic Cyclin E fragment (p18-CycE) was shown to facilitate DNA-damage-induced senescence ([@bb0285]).Fig. 2The potential role of mitophagy in senescence. A) Diagram showing the process of autophagy, exemplified by mitophagy. Cytoplasmic contents including organelles such as mitochondria are sequestered into double-membraned phagophore structures. This process can be selective and involves a number of receptor proteins; specifically for mitochondria these include NDP52, optineurin and TAXBP1. These receptor proteins bind to poly-ubiquitinated proteins which, via binding to the phagophore-resident protein LC3, recruit their cargo to the growing autophagosome. Ubiquitination of mitochondrial surface proteins can occur via stabilisation of PINK1 (PTEN-induced kinase 1) on the mitochondrial surface, which recruits the E3 ubiquitin ligase, Parkin to mitochondrial membranes, thus promoting the ubiquitination and clearance of damaged mitochondria. The fully enclosed autophagosome is trafficked to and fuses with lysosomes. The contents of the subsequent autolysosome are degraded by lysosomal enzymes including hydrolases and proteases. mTORC1 integrates intra- and extra-cellular signals and drives cell growth as well as inhibiting autophagy. B) In young proliferating cells, mTORC1 carefully balances anabolic vs catabolic metabolism in response to the cellular environment. Both mTORC1 activity and autophagy are elevated in senescent cells while the specific process of mitophagy is reduced (see text for more details). Autophagy has a complex relationship with senescence and can both promote and inhibit senescence and senescence-associated phenotypes. For example in the context of OIS, autophagy induction can either promote or suppress acquisition of senescence while the specific role of mitophagy in OIS is currently less clear. Conversely, lifespan-extending interventions such as caloric restriction and rapamycin induce autophagy and mitophagy and relieve senescence-associated phenotypes.Fig. 2

At the same time, autophagy is well accepted as a protective, anti-aging process ([@bb0260]) and, consistent with this notion, a number of reports strongly implicated autophagy in the prevention of cellular senescence. In young, proliferating cells, inhibition of autophagy leads to senescence, at least in part mediated by accumulation of reactive oxygen species and activation of the tumour suppressor and senescence inducer protein p53, suggesting that autophagy suppresses senescence ([@bb0155]). Similarly, in models of mitochondria-targeted damage or oxidative-stress induced senescence, autophagy was shown to retard acquisition of senescence. Mitochondrial damage increased expression of autophagy genes *LC3B*, *ATG5* and *ATG12* and enhanced mitophagy which postponed senescence and enhanced replicative lifespan while peroxide treatment impaired autophagy flux resulting in senescence ([@bb0190], [@bb0305]). Activation of autophagy by inhibition of mTORC1 was shown to efficiently suppress senescence phenotypes in a number of studies ([@bb0095], [@bb0075], [@bb0305]). In contrast to the earlier reports suggesting an OIS-promoting role of autophagy ([@bb0225], [@bb0345]) more recent reports have shown that autophagy can act as a mechanism to bypass RAS-induced senescence and facilitate tumour growth ([@bb0330]).

This contradictory role of autophagy in senescence may be explained, at least in part, by the complex nature of the autophagy process. For example, increased numbers of autophagic vesicles could indicate either increased autophagy or reduced flux, e.g. due to defective trafficking, fusion with lysosomes or defective lysosomal compartment. Moreover, different levels of autophagic activity can mediate different cellular responses to stressors, as it has been suggested in case of RAS-induced senescence. Thus, high levels of autophagy may prevent OIS acquisition, low levels may accompany it whilst more stringent inhibition of autophagy may promote senescence ([@bb0330]). Moreover, timing of autophagy inhibition is likely to be an essential factor for the development of senescence. As described above, rendering autophagy dysfunctional in young cells leads to senescence acquisition whilst in senescent cells autophagy frequently appears to become upregulated, which may be important for the establishment of senescence phenotypes. Finally, a number of senescence regulators that either activate or suppress senescence can be degraded by autophagy. Therefore, inhibition of autophagy may differentially impact on the process of senescence acquisition depending on the relative expression of these autophagy substrates, type of inhibition etc. As an example, it has been suggested that selective autophagy may suppress senescence through the degradation of the pro-senescence factor GATA4 whilst senescence may indeed be promoted by general autophagy through the TASCC ([@bb0150], [@bb0225]).

3.2. Mitophagy and cell senescence {#s0025}
----------------------------------

Similar to other selective autophagy pathways, in mitophagy, specificity is accomplished by a number of dedicated proteins, specifically the PTEN-induced putative kinase PINK1 and Parkin, which ensure that mitochondria with reduced membrane potential are targeted to nascent autophagic vesicles by tagging them with polyubiquitin chains ([Fig. 2](#f0010){ref-type="fig"}A). Ubiquitylated mitochondria are recognized by a set of receptor proteins including optineurin, NDP52 and TaxBP1 which in turn recruit autophagic membranes engulfing and isolating mitochondria. Mitophagy is important for the maintenance of cellular function and viability as evidenced from familial age-related diseases caused by mutations in genes encoding mitophagy components ([@bb0085]).

Interestingly, the regulation and functional role of mitophagy in cell senescence appears to be at least in part independent of changes in general autophagy ([Fig. 2](#f0010){ref-type="fig"}B). While general autophagy may become elevated or reduced depending on the model of senescence, mitophagy activity is reduced in senescent cells in vitro and in vivo ([@bb0080], [@bb0125]). Several potential mechanisms may be responsible for this impairment of mitophagy activity. It may be a consequence of reduced basal or induced autophagic activity, which in turn may result from changes in its upstream regulators like mTOR. Indeed, in senescent cells activity of mTORC1 appears to be elevated ([@bb0075], [@bb0080], [@bb0095]) and become unresponsive to starvation signals. Likewise, lysosomal overload will disrupt the terminal events of substrate degradation in both general autophagy and mitophagy pathways ([@bb0105]). Indeed, despite an extensive expansion of the lysosomal compartment during cell senescence, lysosomal activity is reduced and lysosomes accumulate undegraded material called lipofuscin not only during aging but also in senescence ([@bb0290]). Lysosomal dysfunction may, at least in part, be driven by growth arrest.

Alternatively, mitophagy may become impaired due to mechanisms independent of general autophagy. Cytoplasmic p53, which accumulates in senescence, interacts with Parkin and prevents its translocation to dysfunctional mitochondria, thus suppressing mitophagy and stabilising senescence ([@bb0010]). Similarly, expression of PINK1 is low in aging lungs, suppressing mitophagy and enhancing the probability of senescence transition ([@bb0050]). PINK1 deficiency also suppresses the process of mitochondrial fission, which is important for mitophagy by facilitating the separation of dysfunctional portions from the mitochondrial network. Reduced dynamics and increased fusion of the mitochondrial network in senescent cells has been proposed to result in the failure to sequester defective components of mitochondrial network for degradation via mitophagy ([@bb0080]). As a result, "old" mitochondria avoid degradation while newly synthesised isolated mitochondria are turned over by mitophagy.

4. SAMD as a cause of senescence and aging {#s0030}
==========================================

Data reviewed so far suggest that senescence is associated with dysregulated mitophagy and a subsequent accumulation of dysfunctional mitochondria. This senescence-associated mitochondrial dysfunction is a significant trigger of multiple dimensions of the senescent phenotype. Dysfunctional mitochondria in senescent cells produce enhanced levels of ROS which aggravate DNA damage and the DNA damage response signalling pathway (DDR), contributing to the development and stability of the senescent growth arrest ([@bb0235]). Moreover, dysfunctional mitochondria release multiple forms of "intracellular danger-associated molecular patterns" (DAMPs), especially ROS and mtDNA fragments, that are recognized by NOD-like receptors (NLR), especially NLRP3, triggering inflammasome assembly and activation of pro-inflammatory cytokines IL-1β and IL-18 ([@bb0275]). Enhanced autophagic clearance of mitochondria suppressed NLRP3 activation ([@bb0220], [@bb0350]). This pathway interacts positively with NF-κB signalling enhancing transcription of many pro-inflammatory genes. Thus, mitophagy failure leading to SAMD may be responsible for the pro-inflammatory arm of the SASP. Interestingly, mitochondrial dysfunction (induced by depletion of mtDNA, mitochondrial sirtuins or by inhibition of the mitochondrial electron transport chain) that did not cause elevated cytoplasmic ROS and did not activate the DDR induced a senescent state that lacked the expression of the vast majority of the cytokines usually seem as part of the SASP ([@bb0335]). Moreover, specific removal of all mitochondria in senescing human fibroblasts by activation of the ubiquitin ligase Parkin rescued the hyperproduction of ROS together with all other examined markers of the senescent phenotype (enlarged cell size, sen-β-Gal production, CDKN1A (p21) and CDKN2A (p16) expression, SASP) except growth arrest ([@bb0075]). The same suppression of the senescent phenotype including major SASP components has been achieved by treatment of cells or mice with the mTOR inhibitor and autophagy activator, rapamycin ([@bb0095], [@bb0075]). Together, these data strongly implicate SAMD as a major driver of the senescent phenotype, especially of the SASP.

Importantly, the interconnections between SAMD, SASP and cell senescence do not form a simple linear cause-effect relationship. There is ample evidence for the existence of multiple positive feedback loops between the major components of the senescent phenotype ([Fig. 3](#f0015){ref-type="fig"}). Positive feedback loops between SASP factors and DDR ([@bb0005], [@bb0175]) or between SAMD and DDR ([@bb0235]) are well documented. It has also been shown that chronic activation of NF-κB not only enhances the SASP but also aggravates ROS production and the DDR in senescence ([@bb0145]) possibly at least in part via a 'non-canonical' function of NLRP3. There is also evidence for intriguing interactions between SASP, SAMD and the extracellular matrix (ECM) ([Fig. 3](#f0015){ref-type="fig"}): Senescent cells are known to negatively impact their surrounding environment, including both bystander cells and composition and structure of the ECM via secretion of matrix metalloproteinases, especially MMP-1, and decreased expression of its endogenous inhibitor TIMP-1 as part of the SASP, resulting in ECM degradation with aging ([@bb0045]). SAMD may play an important role for these degenerative changes, as they can be triggered by retrograde signalling in response to mtDNA mutations and electron transport chain dysfunction ([@bb0170], [@bb0335]). ECM collagenolysis autonomously inhibits further pro-collagen synthesis and down-regulates hyaluronic acid synthase 2 ([@bb0255]), further contributing to ECM degeneration. Hyaluronic acid is a linear polysaccharide with pro- or anti-proliferative properties depending on its molecular weight; the extremely high molecular weight hyaluronic acid produced by naked mole rats is a major determinant of their remarkable tumour resistance because of its strong anti-proliferative effect ([@bb0310]). It is thus probable that ECM remodelling by senescent cells feeds back into aggravation of the senescent phenotype and mitochondrial dysfunction in the matrix-embedded cells. Together, these data show that mitochondrial dysfunction is both a cause and a consequence of senescence. Thus, mitochondrial turnover and especially mitophagy might be the central regulator of cell senescence ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3The cell senescence signalling network. Signals downstream of the DDR cause mitochondrial dysfunction via p38MAPK and TGFβ, SASP and chronic inflammation via NF-κB and C/EBPβ and may directly or indirectly suppress autophagy and mitophagy. SASP and mitochondrial dysfunction feedback to maintain and enhance DNA damage at least partly via ROS generation. Many potential interactions within the network (indicated by red arrows) are still insufficiently understood. See text for further details.Fig. 3

5. Outstanding questions {#s0035}
========================

Mitochondrial dysfunction is well accepted as a driver of tissue and organism aging with potential to modulate aging either positively or negatively depending on a set of insufficiently understood conditions ([@bb0325]). An important question is to what extent aging-associated mitochondrial dysfunction and cell senescence/SAMD are interrelated. Does aging-related mitochondrial dysfunction cause senescence in vivo or vice versa? Is mitochondrial dysfunction in aging actually a mosaic phenomenon, occurring preferentially or exclusively in the senescent cells? Given the high prevalence of senescent cells in many tissues (see above), this appears highly possible. Emerging data suggest that it is SAMD rather more than general loss of mitochondrial function in aging that reduces homeostatic capability, causing compromised responses to peak energy demand and driving metabolic insufficiency in aging. For instance, we have found that SAMD in hepatocytes (and other cell types) includes a compromised capacity to metabolize fatty acids, which causes cell-autonomous lipid storage in aging liver and thus contributes to fatty liver (steatosis), a common and pathologically significant complication of liver aging (Ogrodnik et al. unpublished). Adipocyte senescence is an essential driver of adipose tissue dysfunction and obesity ([@bb0300]), and this link is very probably mediated by SAMD. Analysing mitochondrial dysfunction in aging tissues at single-cell resolution in combination with interventions that selectively ablate senescent cells (senolytics) will enable a better understanding of the importance of SAMD in aging.

SAMD appears to be a central mediator for interventions that extend healthy lifespan. Dietary restriction induces autophagy, improves mitochondrial function, specifically in complex I ([@bb0200]) and reduces frequencies of senescent cells in many tissues ([@bb0320]). Similarly the dietary restriction mimetic rapamycin, which also prolongs healthy lifespan in many species by activating autophagy ([@bb0165]) and improving mitochondrial complex I function ([@bb0200]), acts as a senostatic, i.e. it inhibits multiple aspects of the senescent phenotype including SAMD ([@bb0095], [@bb0075]). Recently, metformin gained increasing attention as a drug that can enhance lifespan and healthspan not only in rodents but also in man ([@bb0030]). Metformin improves mitochondrial complex I function ([@bb0120]), inhibits mTORC1 signalling by activating AMPK ([@bb0135]) and blocks pro-inflammatory NF-κB signalling ([@bb0270]). While metformin may sensitize some cell types to stress-induced senescence in vitro, it inhibits the SASP, thus blocking senescent cell-induced bystander effects ([@bb0210]) and may act as a senostatic drug in vivo similar to rapamycin.

Senescent cells typically upregulate anti-apoptotic pathways, and are preferentially susceptible to inhibition of these pro-survival mechanisms. This has been dubbed the 'Achilles heel' of senescent cells and used as a rationale for the development of senostatic drugs (Kirkland & Tchkonia, in this volume). It is tempting to speculate that the low mitochondrial membrane potential found in many senescent cells lies at the heart of this preferential sensitivity by easing the release of apoptosis-stimulating factors from mitochondria. Interestingly in this respect, a recent screen of compounds that modify autophagy (and possibly mitophagy) identified a large number of these as potential senolytics (Fuhrmann-Stroissig et al., unpublished). It seems probable that for drugs to effectively extend such a multifaceted phenotype as healthy lifespan they need to target not just a singular molecular node but a complex network of aging-determining pathways and mechanisms like the one defined by the interactions between mitophagy, SAMD and SASP in cell senescence (see [Fig. 3](#f0015){ref-type="fig"}). We believe that improved understanding of this network will offer an exciting avenue in the development of novel interventions that can prolong healthy lifespan including senolytic and senostatic agents.
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[^1]: RS, Replicative senescence; OIS, Oncogene-induced senescence; SIS, Stress-induced senescence.
